Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$460.73 ▲ +8.90
(+1.97%)
MKT CAP: $249.09B • VOL: 2.98M
52W L $292 52W H $476
AMGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $36.75B | $33.42B | $28.19B |
| YoY Revenue Growth % | +10.0% | +18.6% | — |
| Gross Profit | $24.71B | $20.57B | $12.40B |
| Gross Margin % | 67.2% | 61.5% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $9.08B | $7.26B | $7.90B |
| Operating Margin % | 24.7% | 21.7% | 28.0% |
| Net Income (GAAP) | $7.71B | $4.09B | $6.72B |
| EBITDA (Normalized) | $10.57B | $8.13B | $8.91B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $9.96B | $11.49B | $8.47B |
| Capital Expenditures (CapEx) | $1.86B | $1.10B | $1.27B |
| Free Cash Flow (FCF) | $8.10B | $10.39B | $7.20B |
| FCF Margin % | 22.0% | 31.1% | 25.5% |
| Return on Invested Capital (ROIC %) | 14.5% | 11.4% | 7.5% |
| Cash & Short-Term Equivalents | $9.13B | $11.97B | $15.07B |
| Total Debt (Short + Long Term) | $50.01B | $56.55B | $32.06B |
| Total Stockholders' Equity | $8.66B | $5.88B | $65.76B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AMGN.